The earnings call for Lexicon Pharmaceuticals was largely positive, marked by significant revenue growth, successful strategic repositioning to an R&D-focused company, and promising advancements in the drug pipeline. However, challenges remain in terms of reduced cash reserves and the dependence on partnerships for future progress.

Company Guidance

During the Lexicon Pharmaceuticals second quarter 2025 financial results conference call, the company provided several key updates and metrics. Revenue for Q2 2025 was reported at $28.9 million, a significant increase from $1.6 million in the same period in 2024, primarily due to $27.5 million in licensing revenue from an agreement with Novo Nordisk. Research and development expenses decreased to $15.7 million from $17.6 million in Q2 2024, reflecting reduced external research costs. Selling, general, and administrative expenses also saw a substantial reduction to $9.4 million from $39.2 million in the prior year, driven by strategic repositioning. Consequently, Lexicon posted a net income of $3.3 million, or $0.01 per share, compared to a net loss of $53.4 million, or $0.17 per share, a year earlier. The company ended the quarter with $168 million in cash, short-term investments, and restricted cash. Lexicon revised its full-year 2025 operating expense guidance downward to a range of $105 million to $115 million, focusing on advancing its clinical programs while maintaining cost discipline.

Strong Revenue Growth

Q2 2025 revenue was $28.9 million, a significant increase from $1.6 million in Q2 2024, primarily due to $27.5 million of licensing revenue from the Novo Nordisk agreement.

Successful Strategic Pivot

Lexicon has successfully transformed into an R&D-focused company, reducing operating expenses significantly and focusing on the advancement of its innovative portfolio.

Promising Drug Development

Advancements in the pilavapadin program with the conclusion of a scientific advisory board validating the 10-milligram dose for future studies and plans for Phase III trials in DPNP.

Partnerships and Global Expansion

Viatris progressing with regulatory submissions and approvals of sotagliflozin in multiple countries, and ongoing collaboration with Novo Nordisk for LX9851.

Reduced Operating Expenses

Quarter-over-quarter operating expenses decreased by $31.9 million due to strategic repositioning and reduced marketing efforts, with full-year operating expense guidance lowered.

Lexicon Pharmaceuticals (LXRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LXRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.07 / -	-0.18	―	―	―
Aug 06, 2025	2025 (Q2)	-0.07 / 0.01	-0.17	105.88% (+0.18)
May 13, 2025	2025 (Q1)	-0.10 / -0.07	-0.2	65.00% (+0.13)
Mar 06, 2025	2024 (Q4)	-0.13 / -0.09	-0.2	55.00% (+0.11)
Nov 12, 2024	2024 (Q3)	-0.16 / -0.18	-0.21	14.29% (+0.03)	―
Aug 01, 2024	2024 (Q2)	-0.18 / -0.17	-0.22	22.73% (+0.05)	―
May 02, 2024	2024 (Q1)	-0.18 / -0.20	-0.17	-17.65% (-0.03)	―
Mar 11, 2024	2023 (Q4)	-0.22 / -0.20	-0.16	-25.00% (-0.04)	―	―
Nov 08, 2023	2023 (Q3)	-0.21 / -0.21	-0.13	-61.54% (-0.08)	―
Aug 03, 2023	2023 (Q2)	-0.17 / -0.22	-0.16	-37.50% (-0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LXRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$1.05	$1.15	+9.52%
May 13, 2025	$0.63	$0.53	-15.87%
Mar 06, 2025	$0.37	$0.39	+5.41%
Nov 12, 2024	$1.19	$1.09	-8.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lexicon Pharmaceuticals (LXRX) report earnings?

Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Lexicon Pharmaceuticals (LXRX) earnings time?

Lexicon Pharmaceuticals (LXRX) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LXRX EPS forecast?

LXRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing